by Kyle Dennis | Oct 13, 2019 | Editorial
I’ve made a career using an event-driven trading style… specifically something I call a catalyst runup strategy in biotech stocks. I’ve averaged over $1M in trading profits over the last four years—largely based on the strategy! The best part is…you don’t have...
by Kyle Dennis | Oct 11, 2019 | Editorial
Stocks still can’t seem to figure out whether they want to break out to new highs or revisit the summer lows… However, traders remain hypersensitive to news headlines—causing a lot of back and forth price action. During periods of uncertainty, I try to stay patient...
by Kyle Dennis | Oct 9, 2019 | Kyle's Trades
It’s been a sloppy start to October… as geopolitical tensions steal headlines from an already jam-packed news-driven market. There’s so much noise right now that it’s been hard to find great setups and follow through… even seasoned traders are finding it difficult. ...
by Kyle Dennis | Oct 9, 2019 | Blog
It’s been a sloppy start to October… as geopolitical tensions steal headlines from an already jam-packed news-driven market. There’s so much noise right now that it’s been hard to find great setups and follow through… even seasoned traders are finding it difficult. ...
by Kyle Dennis | Oct 6, 2019 | Kyle's Trades
When you think about trading biotech or pharmaceutical stocks… the first thing that pops into most people’s mind is, Johnson & Johnson, Merck & Co. or Novartis… Companies like Melinta Therapeutics and Chiasma are foreign to most casual traders. However, if...
